Table 2.
Baseline clinical characteristics
| No-PPMI | PPMI | P-Value | |
|---|---|---|---|
| Number of patients | 444 | 168 | |
| Age, years | 80.1 ± 6.1 | 81.1 ± 5.5 | 0.08 |
| Female | 244 (55.0%) | 80 (47.6%) | 0.11 |
| BMI (kg/m2) | 26.9 ± 4.6 | 27.2 ± 5.0 | 0.48 |
| NYHA functional class III/IV | 350 (81.1%) | 127 (75.6%) | 0.13 |
| Diabetes mellitus | 140 (31.5%) | 43 (25.6%) | 0.15 |
| Severe chronic renal failure | 43 (9.7%) | 20 (11.9%) | 0.42 |
| Coronary artery disease | 268 (60.8%) | 106 (63.5%) | 0.54 |
| History of myocardial infarction | 60 (13.5%) | 24 (14.3%) | 0.80 |
| History of cardiac surgery | 47 (10.6%) | 15 (8.9%) | 0.64 |
| History of stroke or intracerebral bleeding | 45 (10.1%) | 18 (10.7%) | 0.83 |
| Pulmonary disease (moderate or severe) | 189 (42.8%) | 78 (46.7%) | 0.38 |
| History of atrial fibrillation | 154 (34.7%) | 66 (39.3%) | 0.30 |
| EuroSCORE II, % | 6.2 ± 5.8 | 6.3 ± 5.5 | 0.84 |
| STS PROM, % | 6.6 ± 4.8 | 6.7 ± 5.2 | 0.89 |
| Echocardiographic data | |||
| Aortic peak gradient, mm Hg | 64.1 ± 22.4 | 66.1 ± 23.3 | 0.33 |
| AVA indexed, cm2/m2 | 0.28 ± 0.08 | 0.28 ± 0.08 | 0.54 |
| Left ventricular ejection fraction (%) | 57.1 ± 15.4 | 58.0 ± 14.7 | 0.51 |
| Left ventricular ejection fraction <45% | 94 (21.2%) | 30 (17.9%) | 0.36 |
| Procedural data | |||
| Implanted valve type: | |||
| – Boston Lotus/Lotus Edge | 127 (28.6%) | 98 (58.3%) | <0.01 |
| – Edwards Sapien 3 | 294 (66.2%) | 66 (39.3%) | <0.01 |
| – Medtronic CoreValve Evolut | 23 (5.2%) | 4 (2.4%) | 0.13 |
| Paravalvular aortic regurgitation | |||
| – None/trace | 343 (77.3%) | 129 (82.7%) | 0.14 |
| – Mild | 101 (22.8%) | 29 (17.3%) | |
| – Moderate/severe | 0 | 0 | |
| Device success | 410 (92.3%) | 154 (91.7%) | 0.78 |
BMI body mass index, NYHA New York Heart Association, STS PROM Society of Thoracic Surgeons Score for predicted risk of mortality, AVA aortic valve area